Getein Biotech

Getein Biotech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Getein Biotech (603387.SS) as of Oct 17, 2026 is 257.01 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 326.25 M CNY — a change of -21.22% (lower).

EBITDA

257.01 MCNY

YoY

-21.22%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Getein Biotech is 2025 257.01 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Getein Biotech was 2024 326.25 M CNY. It decreases by -21.22% lower compared to the previous year.

The Getein Biotech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
296.69 M CNY
Jan 1, 2019
414.71 M CNY
Jan 1, 2020
397.20 M CNY
Jan 1, 2021
484.06 M CNY
Jan 1, 2022
611.77 M CNY
Jan 1, 2023
374.64 M CNY
Jan 1, 2024
326.25 M CNY
Jan 1, 2025
257.01 M CNY
The Getein Biotech EBITDA history
YEAREBITDAYoY
257.01 MCNY-21.22%
326.25 MCNY-12.92%
374.64 MCNY-38.76%
611.77 MCNY+26.38%
484.06 MCNY+21.87%
397.20 MCNY-4.22%
414.71 MCNY+39.78%
296.69 MCNY+26.88%
233.83 MCNY+46.84%
159.24 MCNY+36.21%
116.91 MCNY+38.69%
84.30 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc, listed on the Shanghai Stock Exchange under ticker 603387.SS, is a biotechnology company headquartered in Nanjing, China. The company went public on July 17, 2017, and currently employs 2,508 full-time staff. Its primary business focuses on the medical health industry chain, with operations centered around in vitro diagnostic reagents and related instruments. The company produces a range of diagnostic reagents, including Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. It also develops diagnostic instruments such as the immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000, and the five classification blood cell analyzer BHA-5000. In addition to manufacturing, Getein Biotech offers testing and agency services. Its products are distributed both domestically within China and internationally. The company maintains a website at www.getein.com.cn for further information. As a biotechnology firm operating in the healthcare sector, Getein Biotech Inc is positioned within the broader health care industry, contributing to diagnostic solutions for medical professionals and institutions. The company's focus on in vitro diagnostics aligns with its role in supporting healthcare systems through advanced testing technologies and equipment. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Getein Biotech is 257.01 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Getein Biotech changed from 326.25 M CNY to 257.01 M CNY, representing a -21.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Getein Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Getein Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Getein Biotech